Hypoglycemia News and Research

RSS

Hypoglycemia, also called low blood glucose or low blood sugar, occurs when blood glucose drops below normal levels. Glucose, an important source of energy for the body, comes from food. Carbohydrates are the main dietary source of glucose.

Pierre Fabre Dermatologie receives FDA marketing authorization for pediatric drug Hemangeol

Pierre Fabre Dermatologie has obtained marketing authorization from the FDA for the pediatric drug Hemangeol (propranolol hydrochloride), which is the first and only approved treatment for "proliferating infantile hemangioma requiring systemic therapy".

18 Mar 2014

Jersey Shore University earns Joint Commission's Gold Seal of Approval for inpatient diabetes care program

Jersey Shore University Medical Center has earned The Joint Commission's Gold Seal of Approval™ for its inpatient diabetes care program by providing the best care available for patients with diabetes, and successfully meeting The Joint Commission's national standards for health care quality and safety.

27 Jan 2014

Novo Nordisk launches insulin delivery device NovoPen Echo in the U.S.

Novo Nordisk, a world leader in diabetes care, today announced the launch of the insulin delivery device NovoPen Echo in the United States. This is the first and only pen device available in the U.S. with half-unit dosing and a memory function that records the dose and time passed since the last injection.

From Novo Nordisk 21 Jan 2014

FDA approves Farxiga tablets to improve glycemic control in adults with type 2 diabetes mellitus

AstraZeneca and Bristol-Myers Squibb Company announced the U.S. Food and Drug Administration approved Farxiga™ [far-SEE-ga] (dapagliflozin), a once-daily oral treatment indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

13 Jan 2014

Copenhagen scientists study link between congenital arrhythmia and hypoglycemia

In a new study, scientists from University of Copenhagen document a connection between congenital arrhythmia and the bodies' ability to handle sugar. The results can be of vital importance for patients with the disease and for the future treatment of diabetes. The new study has just been published in the scientific journal Diabetes.

19 Dec 2013

Janssen receives complete response letter for canagliflozin/metformin FDC therapy for type 2 diabetes

Janssen Research & Development, LLC (Janssen) today announced it has received from the U.S. Food and Drug Administration (FDA) a complete response letter regarding its New Drug Application (NDA) for a fixed-dose combination (FDC) of canagliflozin and immediate-release metformin to treat adults with type 2 diabetes.

16 Dec 2013

Emergent BioSolutions enters into definitive agreement to acquire Cangene

Emergent BioSolutions Inc.announced that it has entered into a definitive agreement with Cangene Corporation (TSX: CNJ) under which Emergent will acquire all of the outstanding common shares of Cangene in an all-cash transaction valued at $3.24 per share on a fully diluted basis for an aggregate purchase price of $222 million.

12 Dec 2013

Older people with diabetes are susceptible to nonfatal cardiovascular complications, hypoglycemic events

Cardiovascular complications and hypoglycemia (low blood sugar) were common nonfatal complications in adults 60 years of age and older with diabetes, according to a study published by JAMA Internal Medicine, a JAMA Network publication.

9 Dec 2013

Linagliptin shows efficacy, tolerability in adults with T2D and liver disease

Boehringer Ingelheim and Eli Lilly and Company announce new data that reinforce the efficacy and tolerability of linagliptin in people with Type 2 Diabetes and liver disease, as well as Asian people with T2D aged 65 years or older.

7 Nov 2013

'Early-term' babies more likely to experience higher risk for adverse health outcomes

Babies considered "early-term," born at 37 or 38 weeks after a mother's last menstrual period, may look as healthy as full-term babies born at 39-41 weeks, but a new study published by University at Buffalo physicians in JAMA Pediatrics has found that many of them are not.

3 Oct 2013

Early-term births associated with higher neonatal morbidity, shows study

Early-term births (37 to 38 weeks gestation) are associated with higher neonatal morbidity (illness) and with more neonatal intensive care unit (NICU) or neonatology service admissions than term births (39 to 41 weeks gestation), according to a study by Shaon Sengupta, M.D., M.P.H., now of the Children's Hospital of Philadelphia and formerly of the University at Buffalo, N.Y., and colleagues.

1 Oct 2013

JDRF applauds FDA approval of Medtronic's MiniMed 530G with Enlite system for T1D

JDRF, the leading global organization funding type 1 diabetes research, today applauded the U.S. Food and Drug Administration for its commitment to ensuring patients in the United States can access insulin pumps that can temporarily stop insulin delivery once sensor glucose levels fall below a predetermined threshold.

From Medtronic 29 Sep 2013

Dextrose gel could treat neonatal hypoglycemia

A cheap and easy-to-administer dextrose gel should be used to treat low blood sugars in newborns (neonatal hypoglycaemia), a common problem that affects up to 15% of otherwise healthy babies, and a preventable cause of brain damage, according to new research published in The Lancet.

27 Sep 2013

Use of insulin pump with sensor reduces rate of severe hypoglycemia

Use of an insulin pump with a sensor that suspends insulin delivery when blood glucose falls below a set threshold reduced the rate of severe and moderate hypoglycemia among patients with type 1 diabetes and impaired awareness of hypoglycemia, according to a study in the September 25 issue of JAMA.

25 Sep 2013

Boehringer Ingelheim, Lilly present post-hoc analysis data from linagliptin clinical trials at EASD 2013

Boehringer Ingelheim and Eli Lilly and Company today announced results from two post-hoc, pooled analyses of data from placebo-controlled clinical trials, which examined the safety of the dipeptidyl peptidase-4 inhibitor linagliptin in adults with type 2 diabetes.

24 Sep 2013

Understanding genetic, physiological basis for metabolic diseases related to circadian function

A new study by a team of University of Notre Dame researchers, which appears in the Sept. 2 edition of the journal PLoS ONE, is a significant step in understanding the molecular genetic and physiological basis for a spectrum of metabolic diseases related to circadian function.

24 Sep 2013

New islet transplantation improves results for patients with type 1 diabetes

The latest approach to islet transplantation, in which clusters of insulin-producing cells known as islets are transplanted from a donor pancreas into another person's liver, has produced substantially improved results for patients with type 1 diabetes, and may offer a more durable alternative to a whole pancreas transplant.

20 Sep 2013

New Type 1 Diabetes competitive landscape map released by TechAtlas Group

TechAtlas Group has announced the release of the latest Type 1 Diabetes competitive landscape map. This particular landscape highlights 71 international companies with over 140 drugs and devices currently on the market and in development.

6 Sep 2013

Researchers identify mechanisms necessary to live without insulin

Several millions of people around the world suffer from insulin deficiencies. Insulin is a hormone, secreted by the beta cells in the pancreas, which plays a major role in the regulation of energy substrates such as glucose.

4 Sep 2013

Anti-diabetic drug alogliptin meets primary endpoint in EXAMINE trial

Patients with type 2 diabetes and high cardiovascular risk due to recent acute coronary syndromes had similar rates of cardiovascular events when treated with the anti-diabetic agent alogliptin compared to placebo according to results of the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial presented at the European Society of Cardiology Congress.

2 Sep 2013